Bris­tol My­ers Squib­b's just-launched MS drug Zeposia makes the cut in key ul­cer­a­tive col­i­tis tri­al

In March, Zeposia be­came the third oral S1P mod­u­la­tor to se­cure US ap­proval for mul­ti­ple scle­ro­sis. Now, the drug has suc­ceed­ed in a key ul­cer­a­tive col­i­tis study.

The im­munomod­u­la­tor, akin to oth­ers in its class, con­trols lym­pho­cyte traf­fick­ing by lim­it­ing the white blood cells to the lym­phat­ic sys­tem, in the lymph nodes, and thwart­ing their abil­i­ty to jam up lymph nodes — pre­clud­ing their abil­i­ty to pen­e­trate the blood­stream and the cen­tral ner­vous sys­tem.

Endpoints News

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters